ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial [version 1; peer review: 2 approved]

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial [version 1; peer review: 2 approved]

Background: Over 13,000 new cases of non-Hodgkin’s lymphoma (NHL) are diagnosed in the UK, with approximately 4,900 attributable deaths each year. Diffuse Large B-cell Lymphoma (DLBCL) is the most common NHL comprising one third of adult NHL cases. R-CHOP (rituximab, cyclophosphamide, doxorubicin, v...

Full description

Bibliographic Details
Main Authors: Andrew Davies, Sharon Barrans, Cathy Burton, Katy Mercer, Joshua Caddy, Fay Chinnery, Laura Day, Diana Fernando, Kirit Ardeshna, Graham Collins, John Radford, Simon Rule, Andrew McMillan, Peter Johnson, Gareth Griffiths
Format: Article
Language:English
Published: F1000 Research Ltd 2020-08-01
Series:F1000Research
Online Access:https://f1000research.com/articles/9-941/v1

Internet

https://f1000research.com/articles/9-941/v1

Similar Items